CTRI/2023/06/053620已完成Unknown
Clinical Study to Assess Safety, Efficacy, & Short-Term ConsumerBenefits of Facial Clay Mask in Healthy Female Subjects
DPKA Universal Consumer Venture Private Limited0 个研究点目标入组 55 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1) Age: 21 to 50 years (both inclusive) old at the time of consent.
- •2) Sex: Healthy human non-pregnant/non-lactating females.
- •3) Frequent users of international brands.
- •4) Females of childbearing potential must have a self-reported negative urine pregnancy test.
- •5) Subjects are generally in good general health as determined from recent medical history.
- •6) The subject is willing and able to follow the study directions, participate in the study,
- •returning for all specified visits.
- •7) The subject must be able to understand and provide written informed consent to participate
- •in the study.
排除标准
- •Subjects must not be enrolled in the study if they meet any one of the following criteria:
- •1) Subject with known allergy or sensitization to cosmetic products.
- •2) The subject has clinically significant skin disease, which may contraindicate participation,
- •including psoriasis, eczema, Skin cancer or other skin pathology.
- •3) Medication which may affect skin response and/or past medical history.
- •4) Individuals with active (flaring) disease or chronic skin allergies (atopic dermatitis/eczema)
- •or those who have recently undergone treatment for skin cancer (within the last 12 months)
- •in the area of testing on the forehead, nose and the cheeks.
- •5) Female volunteers who have started a new hormonal birth control agent or switched to a
- •hormonal birth control agent within the past 60 days.
- •6) Individuals who have had any medical or cosmetic procedure, such as laser resurfacing, or
- •plastic surgery to the test site (face) within the last 6 months. This includes botulinum toxin,
- •dermal fillers, collagen or other similar cosmetic procedure.
- •7) Individuals who are currently using or during the past 14 days have used a retinoid such as
- •tretinoin, adapalene, or retinol containing agents or a hydroquinone containing agent.
- •8) Individuals who have used mineral clay masks on their face within the last 14 days.
- •9) Individuals who have been on any topical prescribed medications for the past 2 weeks.
- •10) An individual who has a medical condition or is taking or has taken a medication which, in
- •the Investigator’s judgment, makes the subject ineligible or places the subject at undue
- •11) Participation in other clinical studies simultaneously.
研究者
相似试验
已完成
Unknown
A Clinical Study to determine Safety, Efficacy, In-Use Tolerability Study of HDSC-022209.CTRI/2023/03/050239Himalaya Wellness Company42
进行中（未招募）
1 期
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in Primary Immunodeficiency Diseases (PID) - NAPrimary Immundeficiency Diseases (PID)MedDRA version: 9.1 Level: LLT Classification code 10064859 Term: Primary immunodeficiency syndromeEUCTR2007-002611-27-GBOctapharma AG5
进行中（未招募）
1 期
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in Primary Immunodeficiency Diseases (PID) - NAPrimary Immunodeficiency Diseases (PID)MedDRA version: 9.1Level: LLTClassification code 10064859Term: Primary immunodeficiency syndromeEUCTR2007-002611-27-FROctapharma AG5
进行中（未招募）
不适用
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in Primary Immunodeficiency Diseases (PID) - NAPrimary Immundeficiency Diseases (PID)MedDRA version: 9.1Level: LLTClassification code 10064859Term: Primary immunodeficiency syndromeEUCTR2007-002611-27-DEOctapharma AG45
已完成
不适用
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in primary immunodeficiency diseasesPrimary immunodeficiency diseases (PID)Haematological DisordersOther immunodeficienciesISRCTN63491981Octapharma AG (Switzerland)45